AstraZeneca: EU accepts new breast cancer drug for review

(CercleFinance.com) - AstraZeneca and its US partner Merck said on Tuesday that the European Medicines Agency has accepted to review Lynparza for patients with metastatic breast cancer.


If approved, Lynparza - which exploits DNA to kill cancer cells - would be the first poly ADP-ribose polymerase (PARP) inhibitor to treat patients with breast cancer in Europe.

AstraZeneca also said this Tuesday that the US Food and Drug Administration (FDA) has accepted its application for moxetumomab pasudotox, which is for the treatment of adult patients with hairy cell leukaemia (HCL).

The FDA's decision date has been set for the third quarter of 2018.



Copyright (c) 2018 CercleFinance.com. All rights reserved.